Torno Capital’s Arcturus Therapeutics ARCT Stock Holding History

Torno Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,700	Closed	-$159K	–	186
2024 Q1	$159K	Buy	+4,700	New	+$167K	0.01%	211

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Torno Capital's ARCT Position: Q2 2024 in Review

Torno Capital sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 4,700 shares — an estimated $159K sold.

Torno Capital first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $159K in Q1 2024. 170 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

Torno Capital reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
Torno Capital sold 4,700 Arcturus Therapeutics shares in Q2 2024, an estimated $159K.
Torno Capital first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
Torno Capital's Arcturus Therapeutics position peaked at $159K in Q1 2024.
170 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Torno Capital's 13F filing for Q2 2024, filed 14 Aug 2024.